Case Studies

Non-exclusive licence from IMBA to ViVerita

Exclusive licence from the Research Center Borstel to pulmedix

The transition from inpatient to outpatient care can lead to an interruption in treatment, particularly in severe mental illness. Dr Jakob Kaminski,…

It began with frustration over inflexible hospital information systems (HIS): time spent on documentation in hospitals is growing, and yet crucial…

Proteomics holds great promise for biomedical research – from understanding disease mechanisms to discovering new biomarkers. Over the past decade,…

For decades, genomic diagnostics focused on just 2% of our DNA – the protein-coding part – leaving the vast ‘dark genome’ largely uncharted. Now,…

What seemed a few years ago to be science fiction is now reality: cell and gene therapy play an important role in the treatment of diseases such as…

Our immune response operates in a state of balance between defence and tolerance. Effector T cells (Teff) are responsible for immune defence, whereas…

While successful tumor surgery can be reassuring for cancer patients, the risk of recurrence remains. This arises when individual cancer cells that…

Bromelain is a mixture of enzymes extracted from the stem of the pineapple plant. It is highly proteolytic and has several effects, including…

Zebrafish are vertebrates and as such surprisingly similar to mammals in terms of their genetics. Over 80 per cent of all disease-relevant human genes…

Macrophages play an important role in cellular immunity, and are responsible for the destruction of pathogenic viruses and, above all, bacteria.…

Pathologists and clinicians take a lot of time to thoroughly analyse complex images such as tissue sections or X-rays – and they still make mistakes.…

Over recent months we have all experienced at first hand the dangers posed by highly infectious diseases. Only a few years ago, this was primarily…

After major surgery it’s not unusual for patients in intensive care units to develop complications. If clinical staff could identify at-risk patients…

More than a billion people have no access to medical care, in many cases due to financial obstacles. They have no health insurance, no savings, often…

Poseida, Demeetra and Hera BioLabs have recently launched a new tool for the targeted alteration of genes that offers an attractive alternative to the…

Dr Thomas Aper, Prof. Mathias Wilhelmi and their team at the Department of Cardiothoracic, Transplant and Vascular Surgery (Director: Prof. Axel…

Teams led by Prof. Joachim Hauber at the Heinrich Pette Institute (HPI) – Leibniz Institute for Experimental Virology and Prof. Frank Buchholz* at the…

For over 15 years, Prof. Thomas Blankenstein and his teams at the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association and at…

T cells are highly potent immune effector cells. Many immunotherapies therefore rely on harnessing them for the destruction of cancer cells. However,…

Never full – some people live with a feeling of extreme hunger from birth. The result is obesity, often from early childhood, caused in certain…

The agreements were signed in summer 2018. The world’s largest vaccine manufacturer, the Serum Institute of India Pvt. Ltd (SII), has acquired a…

CAR T and CAR NK cell therapies are the current rays of hope for cancer treatment. The patient’s own T cells or NK cells – the immune system’s…

Everyone has back pain at some point or other. Between 20 and 30% of Europeans have chronic back pain, and in 5% of these cases the cause is…

Around 400,000 people in Germany suffer a heart attack each year. In a fifth of those affected, this leads to a complex process of restructuring in…

In 2017 Ascenion also supported the transfer of EU-financed research projects, for example as a consortium partner on projects in the European…

The vision of introducing genes into human cells to heal life-threatening diseases is more than 50 years old. Today, the first gene therapies are…

The art of a successful breast cancer operation lies in being able to remove as much cancerous tissue as possible and avoid the formation of…

Pseudomonas aeruginosa is a much-feared hospital germ. It can cause dangerous infections, is extremely resilient, and has acquired multiple resistance…

With Ascenion‘s help, the MDC established a unique translational centre in 2016 - the ‚Max-Delbrück Center Cell Engineering Lab‘ (MD-CEL). Its goal is…

In September 2016 the Max Delbrück Center for Molecular Medicine (MDC) and the WILEX subsidiary Heidelberg Pharma signed an option agreement with the…

2016 saw the market launch of a new test from Roche Diagnostics: Elecsys GDF-15. Based on research by Prof. Kai C. Wollert at the Hannover Medical…

Funding of EUR 3.5 million was secured in June 2016 by Prof. Reinhard Zeidler and his team at the Helmholtz Zentrum München. The support comes from…

Chronic Obstructive Pulmonary Disease is characterized by the persistent narrowing of the airways, often leading to difficulties in breathing and…

EUR 9 million Series A financing was secured by HepaRegeniX at the end of 2016 – sufficient to further advance its innovative approach to the…

Meningococci, the main pathogens of bacterial meningitis, still cause epidemics in certain regions in the world, for example in Africa and India.…

July 2015 saw the start of a Phase II clinical study in South Africa – a tuberculosis hot spot. For the first time, infants exposed to HIV received…

In the past year, Ascenion intensively accompanied the spin-off amcure as part of the Spinnovator programme. This start-up from the Karlsruhe…

In December 2015, a new drug was approved in the USA for patients suffering from a rare form of von Willebrand disease. Due to an inherited defect,…

Patients suffering from a rare form of acute lymphoblastic leukaemia (ALL) now have a new treatment option: BLINCYTO (Blinatumomab), an antibody…

Ascenion’s parent company, the LifeScience Foundation for the Promotion of Science and Research, has provided funding of nearly EUR 0.5 million for…